According to a study of 134,000 Medicare patients, conducted by FDA, and published in Circulation on October 30, Boehringer Ingelheim’s Pradaxa was associated with significantly reduced risks of ischemic stroke, intracranial hemorrhage, as well as an increased risk of major gastrointestinal hemorrhage when compared to warfarin in patients with non-valvular atrial fibrillation. The study found no difference in major bleeding episodes between Pradaxa and warfarin.